GSK plc 6-K, filed Feb 12, 2021
GSK plc (GSK)
6-K
2021-02-12
For: 2021-02-12
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on February 12, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
2021 Performance Share Plan Award and 2021 Performance
Measures
2021 Performance Share Plan Award
On 10 February 2021, the Company granted conditional share awards
to the Persons Discharging Managerial Responsibilities ('PDMRs')
and their Persons Closely Associated ('PCAs') listed below under
the GlaxoSmithKline 2017 Performance Share Plan ('the Plan'). The
Plan was approved by shareholders on 4 May 2017 and allows a
performance-related opportunity in the form of conditional awards
to be granted to senior executives in the Group, including the
Executive Directors and other PDMRs.
Under the terms of the Plan, conditional awards are granted over a
specific number of Ordinary Shares or American Depositary Shares
('ADSs'), and the percentage of awards that ultimately vests is
dependent on the level of achievement against performance targets
set by the Remuneration Committee.
2021 Performance Measures
The performance period for the awards is the three financial years
from 1 January 2021 to 31 December 2023. In accordance with
the current Remuneration Policy, the awards will be based on four
measures:
|
Performance Measure
|
Proportion of
each award
|
|
Relative
Total Shareholder Return (TSR)
|
30%
|
|
Adjusted
Free Cash Flow (AFCF)
|
30%
|
|
Innovation
Sales (previously R&D New Products)
|
20%
|
|
Pipeline
Progress
|
20%
|
Relative TSR measure
This measure compares the TSR of the Company's Ordinary Shares over
the performance period with the TSR of the shares of nine (9) other
global pharmaceutical companies (i.e. a comparator group of ten
(10) companies including the Company). This TSR comparator group
remains unchanged. The companies in the TSR comparator group are
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson &
Johnson, Merck & Co, Novartis, Pfizer, Roche Holdings, Sanofi
and GlaxoSmithKline.
In a group of 10 companies, the median (position 5.5) falls between
two companies. The vesting schedule for the 2021 awards is as
follows:
|
Ranking position
|
Vesting Schedule
|
|
1st,
2nd or 3rd
|
100%
|
|
4th
|
70%
|
|
5th
|
40%
|
|
Median
(Threshold vesting)
|
25%
|
|
6th or
below
|
0%
|
Adjusted Free Cash Flow (AFCF) measure
The use of cash flow as a performance measure is intended to
recognise the importance of effective working capital management
and of generating cash to fund the Group's operations, investments,
and ordinary dividends to shareholders.
Free cash flow represents the operating profit of the business
adjusted for non-cash items after deducting the cost or benefit of
working capital, capital expenditure, contingent consideration
payments, net interest, dividends paid to non-controlling interests
and taxation.
The adjustments to free cash flow, used to set the AFCF target for
the purpose of this performance measure, include foreign exchange,
legal, special pension contributions, and the impact of divestments
and acquisitions. The measure post-adjustment is the
"adjusted free cash flow" target.
This element of the 2021 award will vest as follows:
|
Performance Level
|
Adjusted Free Cash Flow target
|
Proportion Vesting
|
|
Below
threshold
|
<
£8.01bn
|
0%
|
|
Threshold
|
£8.01bn
|
25%
|
|
|
£8.26bn
|
50%
|
|
|
£9.08bn
|
75%
|
|
Maximum
|
£9.50bn
|
100%
|
The proportions vesting between the above vesting levels will be
calculated on a straight-line basis.
Innovation Sales measure
Due to commercial sensitivity, the Remuneration Committee remains
of the view that the Innovation Sales measure product target cannot
be published at the time of grant. However, the target and
vesting outcome will be disclosed in full at the end of the
performance period.
25% of this element will vest if the performance threshold level is
attained, rising to 100% for stretching performance exceeding 122%
of the set threshold. Below the set threshold, none of this
element will vest.
Pipeline Progress measure
The Pipeline Progress measure, introduced in 2020, further
increases our emphasis on Innovation and seeks to reward
acceleration and strengthening of the pipeline. The measure is
based on two equally weighted elements of our key assets or
indications:
|
Proportion of award
|
Pipeline Progress - Sub-measure
|
|
10%
|
Pivotal trial starts, which focus mainly on phase III
registrational trial starts, but may also include phase II starts
(for example, in oncology)
|
|
10%
|
Major regulatory approval milestones
|
Points will be allocated to the successful assets in each
sub-measure based upon their forecast commercial value (peak year
sales) at the end of the performance period.
These sub-measures of the 2021 award will vest as
follows:
Pivotal Trial Starts
|
Performance Level
|
Points
|
Payout
|
|
Below
Threshold
|
<12
|
Nil
|
|
Threshold
|
12
|
25%
|
|
|
14
|
50%
|
|
|
15
|
75%
|
|
Maximum
|
17
|
100%
|
Major Regulatory Approvals
|
Performance Level
|
Points
|
Payout
|
|
Below
Threshold
|
<13
|
Nil
|
|
Threshold
|
13
|
25%
|
|
|
15
|
50%
|
|
|
17
|
75%
|
|
Maximum
|
19
|
100%
|
Where relevant, achievements between the above performance levels
will be rewarded on a straight-line basis. As with the
Innovation Sales measure, due to commercial sensitivity, the
Remuneration Committee remains of the view that the Pipeline
Progress measure targets cannot be published at the time of
grant. At the end of the performance period we will provide
full disclosure of what has been achieved, in terms of both
milestones and aggregate points, along with a narrative commentary
on performance.
Notes
1.
To the extent that each element of a conditional award does not
vest at the end of the three-year performance period, it will
lapse.
2.
The PDMRs in the transaction notifications below were each granted
a conditional award under the terms of the GlaxoSmithKline 2017
Performance Share Plan. Awards granted are of Ordinary Shares
or ADSs.
3.
Dividends will accrue on the conditional award of Ordinary Shares
or ADSs during the performance period, but will only vest to the
extent that the awards themselves vest at the end of the
performance period. These dividends are not included in the figures
below.
4.
For Executive Directors, the award is subject to an additional
vesting period of two years (the 'Holding Period') from the normal
vesting date, i.e. five years in total. During the
additional Holding Period, the relevant Ordinary Shares or ADSs
would only be forfeited in the event that the Executive
Director was terminated for cause, and the Ordinary Shares or ADSs
will continue to carry rights to dividend
equivalents.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
550,757
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr I Mackay
|
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
|
278,363
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr H Barron
|
|
|
b)
|
Position/status
|
Chief
Scientific Officer and President, R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of ADSs under the Company's 2017 Performance
Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$35.75
|
254,794
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R Connor
|
|
|
b)
|
Position/status
|
President,
Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
218,299
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms D Conrad
|
|
|
b)
|
Position/status
|
SVP,
Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
111,589
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr J Ford
|
|
|
b)
|
Position/status
|
SVP
& General Counsel
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
|
173,569
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr N Hirons
|
|
|
b)
|
Position/status
|
SVP,
Global Ethics and Compliance
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
68,441
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms S Jackson
|
|
|
b)
|
Position/status
|
SVP,
Global Communications & CEO Office
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
65,826
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D Jackson
|
|
|
b)
|
Position/status
|
PCA of
Ms S Jackson (SVP, Global Communications & CEO
Office)
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
|
5,570
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr B McNamara
|
|
|
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of ADSs under the Company's 2017 Performance
Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$35.75
|
118,097
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr L Miels
|
|
|
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
244,372
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D Redfern
|
|
|
b)
|
Position/status
|
Chief
Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
201,409
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R Simard
|
|
|
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
166,014
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms K Terrell
|
|
|
b)
|
Position/status
|
Chief
Digital & Technology Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of ADSs under the Company's 2017 Performance
Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$35.75
|
98,320
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
20201-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr P Thomson
|
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
92,012
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms D Waterhouse
|
|
|
b)
|
Position/status
|
CEO of
ViiV Healthcare
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
117,462
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms V Whyte
|
|
|
b)
|
Position/status
|
Company
Secretary
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.77
..
|
11,800
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2021-02-10
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
12, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|